Silence Therapeutics Prices Upsized $175 Million Offering After Positive Divesiran Data
Silence Therapeutics priced an underwritten public offering of American Depositary Shares expected to generate approximately $175 million in gross proceeds, upsized from an initially announced $150 million target, one day after reporting positive Phase…
